NCT02934568 2026-04-16
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis
Phase 2 Active not recruiting
Clinical Trials
3,040 trialsNCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
NCT03460977 2026-04-16
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
NCT03853616 2026-04-16
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Miltenyi Biomedicine GmbH
Phase 1 Active not recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT04421963 2026-04-16
ROSY-O
AstraZeneca
Phase 3 Active not recruiting
NCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT04661150 2026-04-16
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT04973605 2026-04-16
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05296798 2026-04-16
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT05475925 2026-04-16
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
Phase 1/2 Recruiting
NCT05552755 2026-04-16
TUPELO
Recursion Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05580562 2026-04-16
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05587296 2026-04-16
OASIS-4
Bayer
Phase 3 Active not recruiting
NCT05925530 2026-04-16
MDT-BRIDGE
AstraZeneca
Phase 2 Active not recruiting
NCT05939414 2026-04-16
PSMA-DC
Novartis
Phase 3 Recruiting
NCT05957367 2026-04-16
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1/2 Recruiting
NCT06049212 2026-04-16
TroFuse-008
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT06057402 2026-04-16
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT06073821 2026-04-16
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT06082960 2026-04-16
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
Phase 1 Active not recruiting
NCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06424340 2026-04-16
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Miltenyi Biomedicine GmbH
Phase 1/2 Recruiting
NCT06451614 2026-04-16
HYDROSPACE
Boston Scientific Corporation
Phase NA Active not recruiting
NCT06467357 2026-04-16
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06496568 2026-04-16
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
Phase 1 Recruiting
NCT06625593 2026-04-16
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06629779 2026-04-16
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT06637501 2026-04-16
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT06708663 2026-04-16
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1/2 Recruiting
NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06746116 2026-04-16
DUoENDE
AstraZeneca
Phase 3 Active not recruiting
NCT06780670 2026-04-16
PSMAcTION
Novartis
Phase 2/3 Recruiting
NCT06784752 2026-04-16
NETTER-3
Novartis
Phase 3 Recruiting
NCT06824467 2026-04-16
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06846671 2026-04-16
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT06991556 2026-04-16
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07005128 2026-04-16
DeLLphi-312
Amgen
Phase 3 Recruiting